Maureen R. Hewitt, MD

Hematology, Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center West Chester
View 2 additional locations
Make an appointmentCall 800-789-7366
Headshot of Maureen R. Hewitt, MD
Penn Medicine Provider

About me

My education and training

  • Medical School: Louisiana State University Hospital
  • Residency: University of Pennsylvania Health System
  • Fellowship: University of Pennsylvania Health System

Spoken languages

English
English

Reviews

Average Rating

1260 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
May 2026
dr. hewitt has a calm and caring demeanor in discussing information that is not always positive. but she knows her stuff, and provides all of the information needed to make informed decisions about treatment.
Anonymous
May 2026
she is kind, knowledgeable and makes me feel comfortable
Anonymous
May 2026
she listened to what i said and made me feel at ease
Anonymous
May 2026
she is a great doctor and takes the time to be thorough, friendly, and compassionate.

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: On the medical staff, but does not have privileges to treat patients in the hospital.
  • Chester County Hospital: Has privileges to treat patients in the hospital.
Dr. Hewitt is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Traynor AM, Hewitt M, Liu G, Flaherty KT, Clark J, Freedman SJ, Leighton AM, Watson PA, Zhao B, O'Dwyer PJ, Wilding G. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced tumors. , Cancer Chemother Pharmacol: 2010

Hewitt M, Sun W, Haller DG, Mykulowycz K, Tuite C, Rosen M, Caparro M, Giantonio B, Oltoff K. A phase II trial of the Combination of Capecitabine, Oxaliplatin with Bevacuzynab in the Treatment of Advanced Hepatocellular Carcinoma Preliminary Safety Analysis. , Proceedings of the American Society of Clinical Oncology: 2006

Hewitt MR, Haller DG. Adjuvant Therapy for Colon Cancer, Yesterday, Today and Tomorrow , The Article Reviewed Oncology (Williston Park), 20: 2006,473-475

Hewitt MR, Yu K. Treatment Update for Metastatic Pancreatic Cancer , Community Oncology, 3: 2006,28-430

Hewitt MR, Sun W. Oxaliplatin-Associated Hypersensitivity Reactions: Clinical Presentation and Management , Clinical Colorectal Cancer, 2(6): 2006,114-117

Hewitt M, Porter DL, Hummel K, McAlee A, Phillips J, Stadtmauer E, Schuster S, Luger S, Nasta S, Tsai D, Loren A, Perl A, Emerson S, Goldstein SC. Myeloablative vs. Non-Myeloablative Conditioning with Allogeneic Stem Cell Transplantation for High Risk Non-Hodgkin's Lymphoma. Similar Outcomes Despite Differences in Disease Risk , Proceedings of the American Society of Bone Marrow Transplantation: 2005

DeCoster MA, Hewitt MR, Lambeau M, Lascunski M, Bazan NG Modulation of Neuronal Sensitivity to Glutamate by Secretory Phospholipases A2 (SPLA2s) , Proceedings of the Society for Neuroscience: 1997